LadaTech

This article has been updated with comments from Illumina.
By a GenomeWeb staff reporter

In its suit, filed last August, LadaTech claimed that Illumina's Genome Analyzer and related products and services infringe a DNA amplification patent it holds.

LadaTech initially filed the suit in August, and said that Illumina refused to enter into a license agreement for the patent.

The suit claims that Illumina's Genome Analyzer and related products and services infringe a patent originally issued to Genelabs and now held by a firm called LadaTech.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.